

Tina M Khadem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7045000/publications.pdf>

Version: 2024-02-01

17
papers

228
citations

1307594

7
h-index

1058476

14
g-index

17
all docs

17
docs citations

17
times ranked

292
citing authors

#	ARTICLE	IF	CITATIONS
1	Launching a comparative effectiveness adaptive platform trial of monoclonal antibodies for COVID-19 in 21Âdays. Contemporary Clinical Trials, 2022, 113, 106652.	1.8	11
2	Evaluation of fidaxomicin use in community hospitals after a clinical guideline change at a large health system and opportunities for stewardship. Infection Control and Hospital Epidemiology, 2022, , 1-3.	1.8	1
3	Development of a Centralized Antimicrobial Stewardship Program Across a Diverse Health System and Early Antimicrobial Usage Trends. Open Forum Infectious Diseases, 2022, 9, .	0.9	5
4	Impact of Clinical Decision Support System Implementation at a Community Hospital With an Existing Tele-Antimicrobial Stewardship Program. Open Forum Infectious Diseases, 2022, 9, .	0.9	4
5	Establishing a Distribution Network for COVID-19 Monoclonal Antibody Therapy Across a Large Health System During a Global Pandemic. Open Forum Infectious Diseases, 2021, 8, ofab151.	0.9	19
6	The UPMC OPTIMISE-C19 (OPTimizing Treatment and Impact of Monoclonal antIbodieS through) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 comparative effectiveness platform trial with response-adaptive randomization. Trials, 2021, 22, 363.	1.6	20
7	Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infectious Diseases, 2021, 8, ofab254.	0.9	59
8	<scp>Teleâ€Antimicrobial</scp> stewardship programs: A review of the literature and the role of the pharmacist. JACCP Journal of the American College of Clinical Pharmacy, 2021, 4, 1016-1033.	1.0	6
9	1987. Impact of Updated IDSA Clostridium difficile Guidelines on the use of Fidaxomicin in a Large Health System. Open Forum Infectious Diseases, 2019, 6, S666-S666.	0.9	3
10	1067. Variation of Antimicrobial Stewardship Programsâ€™ Membership and Organization Within a Single Health System. Open Forum Infectious Diseases, 2019, 6, S378-S378.	0.9	0
11	2083. A Targeted Remote Audit and Feedback Intervention Utilizing a Local Non-ID Trained Pharmacist. Open Forum Infectious Diseases, 2019, 6, S702-S703.	0.9	0
12	Current practices and safety of medication use during rapid sequence intubation. Journal of Critical Care, 2018, 45, 65-70.	2.2	46
13	Evaluation of a Hepatitis C Patient Management Program at a University Specialty Pharmacy. Annals of Pharmacotherapy, 2017, 51, 307-314.	1.9	13
14	Risk factors for carbapenem-nonsusceptible Pseudomonas aeruginosa : Caseâ€™control study. Diagnostic Microbiology and Infectious Disease, 2017, 89, 146-150.	1.8	6
15	New Thoughts on the â€™Forgottenâ€™Aspect of Antimicrobial Stewardship: Adverse Event Reporting. Pharmacotherapy, 2015, 35, 59-63.	2.6	2
16	How Safe Are Recently FDA-Approved Antimicrobials? A Review of the FDA Adverse Event Reporting System Database. Pharmacotherapy, 2014, 34, 1324-1329.	2.6	5
17	Antimicrobial Stewardship: A Matter of Process or Outcome?. Pharmacotherapy, 2012, 32, 688-706.	2.6	28